Trial intelligence / Profile preview

Treatment extension in chronic hepatitis C genotype 2/3 without rapid virological response

2008-000706-36Phase 4Terminated

Sponsor
Hannover Medical School
Start
May 2008
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection (2 arms), sponsored by Hannover Medical School. Started May 2008; status: terminated.

02

Drugs

peginterferon alfa-2bribavirin
03

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2008-000706-36.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-000706-36.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call